Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function

• Autores: Jon Zugazagoitia, A. Manzano, Javier Sastre Valera, José María Ladero Quesada, Javier Puente Vázquez, Eduardo Díaz-Rubio García
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 15, Nº. 2, 2013, págs. 146-153
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective Sorafenib is the standard treatment of patients with advanced hepatocellular carcinoma, regardless of the liver functional reserve. We present a single institutional series of Child�Pugh A and Child�Pugh B patients treated with sorafenib with the aim to establish the efficacy and safety of sorafenib in patients of daily clinical conditions and to compare these results between Child�Pugh A and Child�Pugh B patients.

    Materials and methods A total of 51 patients were treated with sorafenib 400 mg/12 h until disease progression or unacceptable toxicity.

    Results The median progression-free survival and overall survival for the overall population were 3.5 and 8.2 months, respectively, with a 1-year survival rate of 27 %. Overall survival was significantly longer for patients Child�Pugh A compared with those with Child�Pugh B liver function (8.7 vs. 4.7 months, respectively). The most common adverse events were fatigue (62.7 %), diarrhea (58 %), hypertension (31.3 %), and hand�foot syndrome (31.3 %), and in most cases grade 1 or 2 according to the NCI-CTC 3.0. Grade 4 liver-related events occurred mainly in Child�Pugh B patients with decompensated cirrhosis at the time of sorafenib initiation (54.5 % of that group).

    Discussion The benefit of sorafenib in Child�Pugh B patients, if exist, may be limited by frequent liver-related events, especially in decompensated patients, and then, toxicity and impact in quality of life should be carefully monitored.